6397 RESULTS
Sort By:
In the absence of truly effective treatments, and in the presence of a rapidly growing, dementia-prone population of elders, it's perhaps no surprise that people are increasingly open to products claiming even the slightest hint of promise, however u
Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime
The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three
A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the Parkinson's Progression Markers Initiative (PPMI) follow
The Alzheimer's Disease Neuroimaging Initiative is the most expensive AD study the NIH has ever funded. Expectations are that it will speak with the authoritative voice of a 58-center, three-year observation of 819 research participants above a curre
Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b
With the nation at war for eight continuous years, and awareness of the dangers of sports concussions on the rise, a new priority—and opportunity—are taking shape for neurodegenerative disease researchers. In a time of austere budgets, the Department of D
Modern Microscopy Skims Surface of Living Minds and Spines Modern Microscopy Plumbs the Depths of Brain Tissue
Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does
Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field
In the Finnish city of Kuopio, neurosurgeons collaborate with neurophysiologists and molecular and cellular biologists to make frontal cortex, dura, intraventricular CSF, skin, fat, and other tissue from hydrocephalus patients available for research purpo
When the first human genome sequence was finished in 2003, it quickly became clear that its seemingly unending stream of letters was not enough to comprehend what makes people tick. All the moving parts that bring the DNA code to life needed to be underst
The European Union is banking on big returns from nanotechnology in the fight against AD. European Union Throws Megabucks at Nanomedicine EU Consortium Applies Nanotechnology to Study AD
Alzforum readers who follow the science of preclinical Alzheimer's and prevention may have heard about three independent but complementary programs that together are laying the groundwork for secondary prevention trials across the spectrum of rare to
A contentious hypothesis about where and how Parkinson’s disease starts off is gaining ground as new studies provide clues in its support. Neuroanatomists Heiko Braak and Kelly Del Tredici, both at the University of Ulm in Germany, have described the dist
No filters selected
